A new study shows that combining multiple patient-level biomarkers can better predict which cancer patients will respond to immunotherapy, though generalizability remains a challenge.
Multimodal Biomarkers Improve Prediction of Immunotherapy Response
A new study shows that combining multiple patient-level biomarkers can better predict which cancer patients will respond to immunotherapy, though generalizability remains a challenge.
Cancer immunotherapy · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.